Embed Size (px)
Citation preview
CORPORATE INNOVATION ASAN ENGINE FOR CHANGE:Molecular Diagnostics
David Okrongly, Ph.D.SVP Molecular Diagnostics
Siemens Healthcare
Copyright © 2008 Siemens Healthcare USA, Inc. All rights reserved.
MagneticResonance
In Vivo Diagnostics (Major Medical Imaging Systems)
ComputedTomography
X-ray MolecularImaging
Immunoassay ClinicalChemistry
Molecular Hematology LabAutomation
Urinalysis Blood Gas
In Vitro Diagnostics (Major Medical Laboratory Systems)
The Era of the Integrated Diagnostics Company is Here
Healthcare IT
Ultrasound Preclinical Imaging
Integrated medical data translated into actionable knowledge
Copyright © 2008 Siemens Healthcare USA, Inc. All rights reserved.
Global health care spending is accelerating
1,80
0
1,89
1
1,98
4
2,09
1
2,21
1
2,36
4
2,58
9
2,81
1
3,00
5
3,22
4 3,83
5 4,26
7
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
0
100
200
300
400
Global Health Care Global Diagnostics
Glo
bal H
ealth
Car
e
4%
15%
Glo
bal D
iagn
ostic
s
Source: World Medical Markets Fact Book 2007, SG Cowen, Kalorama, TriMark, Management Estimate
New science and aging population further burden spending
$US Bil
Source: SG Cowen
<2%
70%
Healthcare spent on IVD Clinical decision contribution
Are we utilizing the Diagnostic Toolbox well?
Copyright © 2008 Siemens Healthcare USA, Inc. All rights reserved.
Highly Active Antiretroviral Drug Therapy
H A A R T
NRTINRTINRTINRTI
NNRTINNRTI
EIEIPIPIPIPI
INTINT
NRTINRTI
PIPI
NRTINRTI
EIEI
NRTINRTI
INTINT
NNRTINNRTI
Most common
EIEI
INTINT
NEW
COMBO
TX
EIEI
Copyright © 2008 Siemens Healthcare USA, Inc. All rights reserved.
Cancer Represents a Much More Challenging Picture
Monoclonal Antibodies
Small Molecule Inhibitors
Copyright © 2008 Siemens Healthcare USA, Inc. All rights reserved.
How to treat Node Negative Breast Cancer …
Molecular markers like Ki67, ErbB2, …
Basic Risk Categories of Node-negative Breast Cancer Patients without treatment
Current Treatmentaccordingto Guidelines
Treatment decisions accordingto molecular classification
NT
Copyright © 2008 Siemens Healthcare USA, Inc. All rights reserved.
Risk of MI
Cardiac Risk Assessment
High risk
Intermediate risk
Low risk77.5%
15%
7.5%
How???Molecular Diagnostics
# of MIs
~33%
~33%
~33%
Copyright © 2008 Siemens Healthcare USA, Inc. All rights reserved.
Copyright © 2008 Siemens Healthcare USA, Inc. All rights reserved.
The Era of Molecular Medicine
Knowledge-Driven ITIn Vitro Diagnosis
Integrate medical information and enable knowledge-driven clinical applications
Molecular Medicine
Leverage novel molecular technologies for risk assessment, early detection and diagnosis of disease
Systems
IT Applications
Assays
Molecular Imaging
Visualize and localize molecular processesin vivo for diagnosis and therapy
Systems Biomarkers
Clinical Applications
TRANSFORMING PATHOLOGY:Emerging technology driving practice
innovation
